Literature DB >> 10993296

Successful IL-2 therapy for relapsing herpes zoster infection in a patient with idiopathic CD4+ T lymphocytopenia.

K Warnatz1, R Draeger, M Schlesier, H H Peter.   

Abstract

Idiopathic CD4+ T lymphocytopenia (ICL) has been defined by the center of disease control as a rare cause of immunodeficiency with a variable clinical course and an unknown aetiology. Here we describe a 65-year old patient with relapsing generalized herpes zoster infection due to ICL and a severe panlymphocytopenia. In vitro assays revealed an enhanced activation of CD8+ T cells and an increased sensitivity of activated CD4+ T cells for cell death. The clinical outcome was substantially improved after starting the patient on a subcutaneous therapy with IL-2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993296     DOI: 10.1016/S0171-2985(00)80068-6

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  9 in total

1.  Fatal varicella zoster virus infection as first manifestation of idiopathic CD4+ T-cell lymphocytopenia.

Authors:  K Hochauf; D Bandt; C Pöhlmann; S Monecke; M Toma; S Trautmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

2.  Idiopathic CD4 lymphocytopenia: Pathogenesis, etiologies, clinical presentations and treatment strategies.

Authors:  Hale Yarmohammadi; Charlotte Cunningham-Rundles
Journal:  Ann Allergy Asthma Immunol       Date:  2017-10       Impact factor: 6.347

Review 3.  Common variable immune deficiency: Dissection of the variable.

Authors:  Charlotte Cunningham-Rundles
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

4.  Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Authors:  Dimitrios I Zonios; Judith Falloon; John E Bennett; Pamela A Shaw; Doreen Chaitt; Michael W Baseler; Joseph W Adelsberger; Julia A Metcalf; Michael A Polis; Stephen B Kovacs; Stephen J Kovacs; Joseph A Kovacs; Richard T Davey; H Clifford Lane; Henry Masur; Irini Sereti
Journal:  Blood       Date:  2008-05-02       Impact factor: 22.113

5.  Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare.

Authors:  T Trojan; R Collins; D A Khan
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

Review 6.  Idiopathic CD4 lymphocytopenia: a case of missing, wandering or ineffective T cells.

Authors:  Dimitrios Zonios; Virginia Sheikh; Irini Sereti
Journal:  Arthritis Res Ther       Date:  2012-08-31       Impact factor: 5.156

7.  Altered responses to homeostatic cytokines in patients with idiopathic CD4 lymphocytopenia.

Authors:  Florence Bugault; Daniela Benati; Luc Mouthon; Ivan Landires; Pierre Rohrlich; Vincent Pestre; Jacques Thèze; Olivier Lortholary; Lisa A Chakrabarti
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

8.  Idiopathic CD4 Lymphocytopenia: Spectrum of opportunistic infections, malignancies, and autoimmune diseases.

Authors:  Dina S Ahmad; Mohammad Esmadi; William C Steinmann
Journal:  Avicenna J Med       Date:  2013-04

9.  Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients.

Authors:  Alexis Régent; Brigitte Autran; Guislaine Carcelain; Rémi Cheynier; Benjamin Terrier; Bénédicte Charmeteau-De Muylder; Alain Krivitzky; Eric Oksenhendler; Nathalie Costedoat-Chalumeau; Pascale Hubert; Olivier Lortholary; Nicolas Dupin; Patrice Debré; Loïc Guillevin; Luc Mouthon
Journal:  Medicine (Baltimore)       Date:  2014-03       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.